{
    "symbol": "VCYT",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-02 18:58:03",
    "content": " Last quarter, the National Comprehensive Cancer Network or NCCN further updated its prostate cancer guidelines, making Decipher, the first and only gene expression test to achieve level one evidence status in prostate cancer. Afirma, our market defining test for thyroid cancer had its strongest quarter so far this year with revenue growth of 6%, compared to the prior year period. At the same time, with multiple early stage products of various phases of development or commercialization and with our strong  As a reminder, our investments in our long-term growth opportunities are primarily focused on the aforementioned Percepta Nasal Swab test in lung cancer, as well as the development of In Vitro Diagnostics or IVD versions of the Envisia, Decipher and Nasal Swab Test for the nCounter instrument. We delivered testing revenue of $64.6 million, an increase of 27% year-over-year, driven by higher than expected Decipher prostate and Afirma volume with last quarter's Afirma supply chain situation now in the rearview mirror. Third quarter product volume was approximately 2,400 tests, resulting in revenue of $3.3 million, up 12% year-over-year, despite a currency headwind of over 10% given prior year rates. This range compared to our previous guidance of $272 million to $280 million, reflects our strong performance in the third quarter, continued outperformance of our urology business, Afirma full-year revenue growth of low to mid single-digits and current currency rates. By the way, firstly, just seeing, I mean, the beat was driven also by, from our standpoint, the Afirma product as well Afirma had a record quarter in terms of volume and I'm extremely proud of what that team has been able to accomplish and how that product continues to grow the market is over 50% penetrated and we keep demonstrating an ability to both bring on new customers."
}